Preliminary Clinical Trial of Biomarkers to Predict Response to Sublingual Immunotherapy for Japanese Cedar Pollinosis

Background: As part of the planning for a future multicenter study, this preliminary clinical trial used serum samples from patients to identify biomarkers for predicting the therapeutic effects of sublingual immunotherapy (SLIT) for Japanese cedar pollinosis (JCP). Methods: This prospective study included patients undergoing SLIT for JCP at our hospital. All enrolled patients ( N = 17) started SLIT between June and November of 2015. With informed consent from the patients, blood samples were obtained in January, March, and June of 2016, and patients completed the Japan rhino-conjunctivitis quality of life questionnaire (JRQLQ). On the basis of the JRQLQ results, the 6 patients with the best outcomes were included in the high-response group (HRG), and the 5 patients with the worst outcomes were included in the poor-response group (PRG). We then compared serum data between the two groups, to identify useful biomarkers. Results: IL-12p70 and VEGF levels tended to be higher in the HRG than in the PRG in January, March, and June (0.10 > p > 0.05). In addition, the June IL-17 level was significantly higher (p < 0.05) in the HRG than in the PRG. Conclusions: IL-12p70 and VEGF may be useful biomarkers for predicting the effects of SLIT. In addi-tion, although IL-17 does not appear to be useful as a biomarker for evaluating treatment response at the start of SLIT, it may be useful as a biomarker after the beginning phase of SLIT. (J Nippon Med Sch 2020; 87: 277 ― 284)

[1]  S. Takao,et al.  Significance of IgG4-positive cells in severe eosinophilic chronic rhinosinusitis. , 2019, Allergology international : official journal of the Japanese Society of Allergology.

[2]  O. Kaminuma,et al.  Serum Cytokine Interactions Are Implicated in the Mechanism of Action of Sublingual Immunotherapy for Japanese Cedar Pollinosis. , 2018, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[3]  M. Caruso,et al.  Basophil biomarkers as useful predictors for sublingual immunotherapy in allergic rhinitis , 2018, International immunopharmacology.

[4]  O. Kaminuma,et al.  Identification of biomarker sets for predicting the efficacy of sublingual immunotherapy against pollen-induced allergic rhinitis , 2017, International immunology.

[5]  O. Kaminuma,et al.  [A biomarker set relation to the efficacy of allergen-specific immunotherapy]. , 2015, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[6]  S. Fujieda,et al.  Long-term sublingual immunotherapy for Japanese cedar pollinosis and the levels of IL-17A and complement components 3a and 5a. , 2015, Cytokine.

[7]  Mingqiang He,et al.  Cytokine Responses to Specific Immunotherapy in House Dust Mite-Induced Allergic Rhinitis Patients , 2015, Inflammation.

[8]  Y. Okamoto,et al.  Efficacy and Safety of Sublingual Immunotherapy for Two Seasons in Patients with Japanese Cedar Pollinosis , 2015, International Archives of Allergy and Immunology.

[9]  S. Fujieda,et al.  [Clinical relevance of biomarkers in allergic rhinitis]. , 2014, Arerugi = [Allergy].

[10]  M. Okano,et al.  Local expression of interleukin-17a is correlated with nasal eosinophilia and clinical severity in allergic rhinitis , 2014, Allergy & rhinology.

[11]  Y. Okamoto,et al.  Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. , 2011, Clinical immunology.

[12]  Y. Kurono,et al.  Vascular Endothelial Growth Factor Produced in Nasal Glands of Perennial Allergic Rhinitis , 2008, American journal of rhinology.

[13]  H. Kiyono,et al.  [Applicable strategies for the mucosal immune system in the regulation of allergic diseases]. , 2008, Arerugi = [Allergy].

[14]  Y. Okamoto,et al.  A Randomized Controlled Trial of Sublingual Immunotherapy for Japanese Cedar Pollinosis , 2007, International Archives of Allergy and Immunology.

[15]  H. Kanazawa,et al.  Up-regulation of thrombin activity induced by vascular endothelial growth factor in asthmatic airways. , 2007, Chest.

[16]  S. Y. Kim,et al.  Vascular endothelial growth factor and plasminogen activator inhibitor-1 in children with recurrent early wheeze. , 2007, The Journal of allergy and clinical immunology.

[17]  Takeshi Shimizu,et al.  Enhanced Clinical Efficacy of Sublingual Immunotherapy for Japanese Cedar Pollinosis in the Second Year of Treatment. , 2017, Nihon Jibiinkoka Gakkai kaiho.

[18]  Takeshi Shimizu,et al.  [CLINICAL EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN THE THIRD TREATED YEAR WITH JAPANESE CEDAR POLLINOSIS IN 2017]. , 2017, Arerugi = [Allergy].

[19]  G. Ciprandi,et al.  Serum specific IgE: a biomarker of response to allergen immunotherapy. , 2014, Journal of investigational allergology & clinical immunology.

[20]  S. Matsune.  Allergic rhinitis and vascular endothelial growth factor. , 2012, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.